Phase I study NCT01628640 evaluates the safety and MTD of VSV-IFNB-hNIS in the treatment of hepatocellular cancer and tumors with metastatic lesions in the liver with two administration formats (injection into one or more lesions, respectively); and in Phase I study, NCT03017820 VSV-IFNB-hNIS is combined with ruxolitinib (JAK inhibitor) for the treatment of a wide range of refractory hematologic cancers. The gene discussed is IFNB1; the disease is hepatocellular carcinoma.